Rich Pharmaceuticals Inc (OTCBB:RCHA) said that it completed a GMP clinical batch of its RP-323 study drug. It was developed at Wuxi Apptec Biopharmaceutical’s facility located in Shanghai, China. The new batch represents a second-generation compound, with improved product stability and usability.
Rich Pharmaceuticals Inc (OTCBB:RCHA) developed the formulation and all regulatory testing methods in 2014. After that it transferred the proprietary technology to Wuxi Apptec. It was done in order to complete GMP production of RP-323. As of now, the experimental drug is in the final testing stage at Wuxi Apptec. The experimental drug is anticipated to be shipped to clinical locations starting February 2015 for the upcoming planned clinical research.
Rich Pharmaceuticals Inc (OTCBB:RCHA) submitted its IND application for a new Phase 2 study to evaluate the efficacy and safety of RP-323 in patients with MDS and AML in last October. In connection with the investigational new drug application, the company was required to make adequate quantities of RP-323 under GMP.
The management view
Ben Chang, the CEO of Rich Pharmaceuticals Inc (OTCBB:RCHA), said that the management believes RP-323 reflects best-in-class potential and significant promise for all the patients suffering from MDS and AML. The company is delighted to have a partner in the development of RP-323 with Wuxi Apptec. Chang expects to get the approval for the investigational drug soon. Rich can start with clinical studies in the coming period.
Rich Pharmaceuticals Inc (OTCBB:RCHA) is a known name in the industry of biopharmaceuticals. It is working on the clinical study that will result in an effective medication for Acute Myelocytic Leukemia, Hodgkin’s Lymphoma and other related diseases. The main objective is to expand patients’ life expectancy and enhance their quality of life. The primary development stage treatment product, RP-323, is being developed to treat blood and cancer related health problems through non-evasive outpatient facilities.